Summary latest Pharmaceutical and Healthcare disease pipeline guide Methicillin-Resistant Staphylococcus aureus Infections - Pipeline Review, H2 2020, provides an overview of the Methicillin-Resistant Staphylococcus aureus Infections (Infectious Disease) pipeline landscape.
MRSA infections that are acquired by persons who have not been recently (within the past year) hospitalized or had a medical procedure (such as dialysis, surgery, catheters) are known as community-acquired MRSA (CA-MRSA) infections. Risk factors are hemodialysis, weakened immune system, admission to hospitals and wounds. Symptoms include skin rashes, fatigue, chest pain, fever and swelling. MRSA can be managed by the use of antibiotics and by maintaining hygienic conditions.
Report Highlights Pharmaceutical and Healthcare latest pipeline guide Methicillin-Resistant Staphylococcus aureus Infections - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Methicillin-Resistant Staphylococcus aureus Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Methicillin-Resistant Staphylococcus aureus Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 8, 14, 8, 3, 76, 32 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 35 and 27 molecules, respectively.
Methicillin-Resistant Staphylococcus aureus Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Methicillin-Resistant Staphylococcus aureus Infections (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Methicillin-Resistant Staphylococcus aureus Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Methicillin-Resistant Staphylococcus aureus Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Methicillin-Resistant Staphylococcus aureus Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Methicillin-Resistant Staphylococcus aureus Infections (Infectious Disease)
Reasons to Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Methicillin-Resistant Staphylococcus aureus Infections (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Methicillin-Resistant Staphylococcus aureus Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Our reports have been used by over 10K customers, including:
299 pages •
By Asia Market Information & Development Company
• Mar 2021
China’s demand for Disposable Medical Supplies has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, import & export, consumer...
The oxygenators market was valued at USD 207 million in 2020, and it is poised to grow at a CAGR of 5.4% during the forecast period, 2021-2026, to reach USD 297 million by 2026. To cope up with the current COVID-19 situation, companies are increasing the production of oxygenators globally to support the adoption of ECMO procedures for...
The specialty PACS market is anticipated to register a CAGR of 4.87%, over the forecast period. - The significant factors attributing to the studied market’s growth is the growing use of visualization and opting for greater collaboration between IT structures and imaging modalities, and diverse medical fields that have been gradually...
In-depth Analysis and Data-driven Insights on the Impact of COVID-19 Included in this Global IV and Oral Iron Drugs Market Report
The global IV and oral iron drugs market by revenue is expected to grow at a CAGR of 11.6% during the period 2021–2026.
The global IV and oral iron drugs market is expected to grow due to the prevalence...
The oncology information systems market is projected to reach USD 9.5 billion by 2025 from USD 6.7 billion in 2020, at a CAGR of 7.4% during the forecast period. Growth of the market is mainly attributed to the technological advancements; increasing incidences of cancer cases, and growing public and private investments, funding, and grants...
The drug discovery market is expected to register a CAGR of nearly 8.3% during the forecast period, with a revenue of approximately USD 53,855 million in 2020, and it is expected to reach 85,785 million by 2026. Amid the COVID-19 pandemic, the health system of countries is rapidly investing in research and development to combat the...
The North America nuclear medicine market was valued at USD 5,624 million in 2020 and is projected to be worth USD 10,273 million by 2026 registering a CAGR of 10.4%, over the forecast period 2021-2026. Several general principles have been implemented by government organizations with key goals to reduce disease transmission, preserve...
In-depth Analysis and Data-driven Insights on the Impact of COVID-19 Included in this US Corporate Wellness Market Report
The US corporate wellness market by revenue is expected to grow at a CAGR of over 9% during the period 2021–2026.
The outbreak of the COVID-19 pandemic in the US has infused high stimulus into the US corporate...
The propelling factors for the growth of the apheresis market include the increasing number of diseases, a rise in the demand for blood components and associated safety, technological advancement in the development of new apheresis techniques, and rise in the reimbursement policies and funding for apheresis procedures. With the increasing...
The global tele-intensive care unit market was valued at USD 3,160 million in 2020 and is expected to reach USD 8,950 million by 2026, registering a CAGR of about 19% over the forecast period. As the COVID?19 pandemic continues to expand throughout the world, innovative methods are required to involve residents in the care of critically...
Surgical Procedures Performed
Medical Technology Density
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.